Table 1.
DEGs selected by biological significance
| Gene symbol | Gene ontology function | Notes | Fold change |
|---|---|---|---|
| ANGPT1 | Secreted protein | Overexpressed in AML, CML, and MDSs | 3.1 |
| ANXA3 | Cytoplasmatic protein | Negative prognostic factor for prostate cancer | 10.4 |
| ARHGAP18 | Cytoplasmatic protein | Involved in cell spreading and motility | 3.0 |
| CD9 | Membrane protein | Involved in platelet activation and aggregation; involved in BM remodeling in PMF | 2.2 |
| CEACAM8 | Membrane protein | Overexpressed in imatinib-resistant CML cells | 5.5 |
| CP | Enzyme | Overexpressed in AML; negative prognostic factor for renal carcinoma | 2.6 |
| DEFA1 | Secreted protein | Overexpressed in imatinib-resistant CML cells; biomarker for diagnosis of CRCA | 60.2 |
| FGR | Kinase | Involved in cell migration | 1.9 |
| FHL2 | Transcription factor | Promotes myeloid proliferation; overexpressed in AML | 2.7 |
| IDH1 | Cytoplasmatic protein | Mutated in MPNs | 2.4 |
| IFI27 | Membrane protein | Involved in defense and immunity | 2.4 |
| IFIH1 | Cytoplasmatic protein | Involved in defense and immunity | 2.3 |
| IKZF2 | Transcription factor | Overexpressed in in Hodgkin lymphoma and ALL | 3.6 |
| ITGB3 | Membrane protein | Involved in platelet activation and aggregation | 2.5 |
| LCN2 | Secreted protein | Expression induced by BCR-ABL protein; negative prognostic factor for breast cancer | 7.0 |
| LEPR | Membrane protein | Overexpressed in AML and PMF; involved in fibrosis | 9.7 |
| MAF | Transcription factor | Negative prognostic factor for MM | 8.0 |
| MEF2C | Transcription factor | Involved in MK differentiation | 2.3 |
| MMP9 | Extracellular matrix protein | Involved in the development of fibrosis | 3.8 |
| MYC | Transcription factor | Involved in MK differentiation; cancer marker | 2.8 |
| NFE2 | Transcription factor | Involved in MK differentiation; overexpressed in PMF | 2.0 |
| OLFM4 | Secreted protein | Negative prognostic factor for colorectal, breast, and lung cancer | 3.5 |
| PF4 | Secreted protein | Involved in platelet activation and aggregation | 3.4 |
| PIM1 | Transcription factor | Overexpressed in PMF | 2.6 |
| RHOB | Cytoplasmatic protein | Involved in cell spreading and motility | 3.7 |
| TIMP3 | Extracellular matrix protein | Involved in the development of fibrosis | 4.0 |
| TM4SF1 | Membrane protein | Involved in cell spreading and motility | 4.4 |
| VWF | Secreted protein | Highly expressed by early MKs; involved in platelet adhesion | 4.4 |
| WT1 | Transcription factor | Negative prognostic factor in AML; associated with high severity score in PMF | 2.0 |
| AFF3 | Transcription factor | Fusion with MLL gene in ALL and with RUNX1 gene, partner of MLL | −2.2 |
| ARHGEF7 | Cytoplasmatic protein | Involved in cell migration, attachment, and cell spreading | −2.2 |
| ARID4A | Nuclear protein | Involved in chromatin remodeling; K/O mice develop myelofibrosis | −2.3 |
| BRWD1 | Nuclear protein | Involved in chromatin remodeling | −1.8 |
| CDC42 | Cytoplasmatic protein | Cdc42-deficient mice developed a fatal myeloproliferative disorder | −4.9 |
| CEBPD | Transcription factor | Myeloid commitment regulator | −2.2 |
| CEBPG | Transcription factor | Myeloid commitment regulator | −2.5 |
| CXCR4 | Membrane protein | Involved in BM homing | −2.5 |
| EIF2AK3 | Kinase | The ablation in tumor cells results in accumulation of ROS | −3.0 |
| FOXO1 | Transcription factor | Involved in OXS response; negative prognostic factor for AML | −2.3 |
| HMGB3 | Nuclear protein | Involved in chromatin remodeling; required for the proper balance between HSC self-renewal and differentiation | −2.5 |
| IRF4 | Transcription factor | Downregulated in CML | −2.7 |
| IRF8 | Transcription factor | Downregulated in CML | −6.4 |
| JARID2 | Nuclear protein | Involved in chromatin remodeling and in AML progression | −2.5 |
| KLF3 | Transcription factor | Downregulated in AML; K/O mice display abnormalities in hematopoiesis | −3.6 |
| MAFF | Transcription factor | Myeloid commitment regulator | −2.0 |
| MEF2D | Transcription factor | Involved in myogenic differentiation; fusion with DAZAP1 gene in ALL | −2.7 |
| MLL5 | Transcription factor | Frequently deleted in human myeloid malignancies | −2.7 |
| MXD1 | Transcription factor | Involved in regulation of cell proliferation; antagonizes MYC gene | −3.4 |
| NR4A3 | Nuclear protein | Involved in chromatin remodeling; hypoallelic mice display MDS/MPNs features | −2.4 |
| NUP98 | Transcription factor | Involved in fusions with different partner genes in patients with hematopoietic malignancies | −2.5 |
| PHC3 | Nuclear protein | Component of polycomb repressive complex | −2.1 |
| PURB | Nuclear protein | Deleted in MDS and AML | −2.5 |
| RUNX2 | Transcription factor | Involved in hematopoietic and osteogenic lineages differentiation | −2.1 |
| SF3B1 | Nuclear protein | Mutated in MDS and in MDS/MPNs | −2.0 |
| SMAD7 | Transcription factor | Involved in fibrosis; downregulated in MDSs | −7.2 |
| TCF4 | Transcription factor | Myeloid commitment regulator | −2.4 |
| TLE4 | Transcription factor | Deleted in AML | −2.2 |
| TP53INP1 | Nuclear protein | Loss of expression in several cancers; inactivation correlates with increased cell migration | −2.5 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCR-ABL, breakpoint cluster region gene-Abelson murine leukemia viral oncogene homolog 1; CML, chronic myeloid leukemia; CRCA, colorectal cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; OXS, oxidative stress; ROS, reactive oxygen species.